(MedPage Today) — CHICAGO — Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115862
Author :
Publish date : 2025-06-02 18:52:00
Copyright for syndicated content belongs to the linked Source.
